<?xml version="1.0" encoding="UTF-8"?>
<p id="Par12">People infected with HIV (PWH) with OUD have an increased incidence of neuroHIV and CNS complications (Bell et al. 
 <xref ref-type="bibr" rid="CR36">1998</xref>; Nath et al. 
 <xref ref-type="bibr" rid="CR359">1999</xref>, 
 <xref ref-type="bibr" rid="CR360">2000a</xref>, 
 <xref ref-type="bibr" rid="CR362">2002</xref>; Anthony et al. 
 <xref ref-type="bibr" rid="CR12">2008</xref>; Meyer et al. 
 <xref ref-type="bibr" rid="CR336">2013</xref>; Smith et al. 
 <xref ref-type="bibr" rid="CR474">2014</xref>). Injection drug use increases the probability of contracting HIV (Nath et al. 
 <xref ref-type="bibr" rid="CR359">1999</xref>) and opioid drugs intrinsically alter the pathogenesis of HIV. PWH who develop intractable pain syndromes related to peripheral neuropathies often receive opioid drugs for treatment (Mirsattari et al. 
 <xref ref-type="bibr" rid="CR339">1999</xref>; Denis et al. 
 <xref ref-type="bibr" rid="CR113">2019</xref>). PWH who misuse opioids are more likely to undertake risky sexual behavior and are less likely to adhere to combined antiretroviral (ARV) therapy (cART) regimens (Lemons et al. 
 <xref ref-type="bibr" rid="CR276">2019</xref>). Opioid receptors are widely expressed on immune cells and opioids can modulate immune function (Donahoe and Falek 
 <xref ref-type="bibr" rid="CR117">1988</xref>; Plotnikoff 
 <xref ref-type="bibr" rid="CR401">1988</xref>; Rouveix 
 <xref ref-type="bibr" rid="CR437">1992</xref>; Adler et al. 
 <xref ref-type="bibr" rid="CR2">1993</xref>; Carr and Serou 
 <xref ref-type="bibr" rid="CR74">1995</xref>; Carr et al. 
 <xref ref-type="bibr" rid="CR75">1996</xref>; Sheng et al. 
 <xref ref-type="bibr" rid="CR463">1997</xref>; Banerjee et al. 
 <xref ref-type="bibr" rid="CR28">2011</xref>; Purohit et al. 
 <xref ref-type="bibr" rid="CR409">2012</xref>), which typically (but not always) result in immune suppression (Wybran et al. 
 <xref ref-type="bibr" rid="CR548">1979</xref>; McDonough et al. 
 <xref ref-type="bibr" rid="CR325">1980</xref>, 
 <xref ref-type="bibr" rid="CR326">1981</xref>; Donahoe and Falek 
 <xref ref-type="bibr" rid="CR117">1988</xref>; Donahoe et al. 
 <xref ref-type="bibr" rid="CR119">1991</xref>; Falek et al. 
 <xref ref-type="bibr" rid="CR149">1991</xref>; Novick et al. 
 <xref ref-type="bibr" rid="CR372">1991</xref>; Chao et al. 
 <xref ref-type="bibr" rid="CR81">1996a</xref>; Peterson et al. 
 <xref ref-type="bibr" rid="CR395">1998</xref>; Rogers and Peterson 
 <xref ref-type="bibr" rid="CR434">2003</xref>; Stein et al. 
 <xref ref-type="bibr" rid="CR482">2003</xref>; Roy et al. 
 <xref ref-type="bibr" rid="CR438">2006</xref>; Rittner et al. 
 <xref ref-type="bibr" rid="CR425">2008</xref>). The “opiate cofactor hypothesis” proposes opioids contribute directly to the pathogenesis of acquired immune deficiency syndrome (AIDS) (Donahoe and Vlahov 
 <xref ref-type="bibr" rid="CR118">1998</xref>), in part, because MOR activation can increase HIV replication in immune cells (Peterson et al. 
 <xref ref-type="bibr" rid="CR392">1990</xref>, 
 <xref ref-type="bibr" rid="CR393">1992</xref>, 
 <xref ref-type="bibr" rid="CR394">1993</xref>, 
 <xref ref-type="bibr" rid="CR396">1999</xref>; Ho et al. 
 <xref ref-type="bibr" rid="CR211">2003</xref>). Furthermore, MOR and HIV co-receptors, including both CCR5 (El-Hage et al. 
 <xref ref-type="bibr" rid="CR137">2013</xref>; Yuan et al. 
 <xref ref-type="bibr" rid="CR557">2013</xref>; Arnatt et al. 
 <xref ref-type="bibr" rid="CR18">2016</xref>) and CXCR4 (Pitcher et al. 
 <xref ref-type="bibr" rid="CR399">2014</xref>) can interact via convergent downstream signaling and perhaps via direct molecular interactions (Rogers et al. 
 <xref ref-type="bibr" rid="CR435">2000</xref>; Rogers and Peterson 
 <xref ref-type="bibr" rid="CR434">2003</xref>; Steele et al. 
 <xref ref-type="bibr" rid="CR481">2003</xref>; Chen et al. 
 <xref ref-type="bibr" rid="CR89">2004</xref>; Song et al. 
 <xref ref-type="bibr" rid="CR476">2011</xref>; Arnatt et al. 
 <xref ref-type="bibr" rid="CR18">2016</xref>). MOR-CCR5 or CXCR4 interactions are highly contextual and can promote (Guo et al. 
 <xref ref-type="bibr" rid="CR192">2002</xref>; Steele et al. 
 <xref ref-type="bibr" rid="CR481">2003</xref>) or inhibit (Strazza et al. 
 <xref ref-type="bibr" rid="CR489">2014</xref>) HIV expression, depending on the nature and duration of exposure (see Fig. 9; Berman et al. 
 <xref ref-type="bibr" rid="CR42">2006</xref>) and cell type involved (Kim et al. 
 <xref ref-type="bibr" rid="CR237">2018</xref>). Depending on the outcome measure, Tat expression reduces morphine’s efficacy and potency (Fitting et al. 
 <xref ref-type="bibr" rid="CR161">2012</xref>, 
 <xref ref-type="bibr" rid="CR164">2016</xref>; Hahn et al. 
 <xref ref-type="bibr" rid="CR200">2016</xref>). Antagonizing CCR5 with maraviroc reinstates morphine potency in an antinociceptive assay and restores physical dependence in Tat exposed, morphine-tolerant mice (Gonek et al. 
 <xref ref-type="bibr" rid="CR183">2018</xref>).
</p>
